Final overall survival and safety analyses of the phase III PSMAfore trial of [177Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer

Karim Fizazi, K.N. Chi, Neal D. Shore, Ken Herrmann, Johann S. de Bono, Daniel Castellano, Josep M. Piulats, Aude Fléchon, Xin Wei, Hakim Mahammedi, Guilhem Roubaud, Mark T. Fleming, T Haas, Samson Ghebremariam, T N Kreisl, S. Rajagopalan, Oliver Sartor, Michael J. Morris, M.J. Morris, Wolfgang Loidl, Ferdinand Luger, Gero Kramer, Isabel Maria Heidegger Pircher, Bertrand Tombal, Nicolaas Lumen, Kristoff Muylle, Nadia Withofs, Kim Nguyen Chi, Gad Abikhzer, Fred Saad, Hana Studentova, Aude Flechon, Karim Fizazi, Karim Fizazi, Hakim Mahammedi, Guilhem Roubaud, Ahmed Khalil, Olivier Morel, Ken Herrmann, Matthias Eiber, James Nagarajah, Thomas Kerkhofs, Marnix Lam, Daria Handkiewicz-Junak, Michal Mego, Joan Carles Galceran, Jose Pablo Maroto Rey, Begona Mellado Gonzalez, Josep Maria Piulats Rodriguez, Daniel Castellano Gauna, Javier Puente Vazquez, Jose Angel Ange Arranz Arija, Aranzazu Gonzalez del Alba, Miguel Angel Climent Duran, Regina Girones Sarrio, Silverio, Ros Martinez, Alvaro Montesa Pino, Begona Perez Valderrama, Jose Luis Perez Gracia, Urbano Anido Herranz, Claes Molin, Enrique Castellanos, Carl-Fredrik Warfvinge, Dominik Berthold, Anja Lorch, Irene Burger, Johann de Bono, Gerhardt Attard, Darren James Leaning, Andrew Chan, Carla Perna, Mark Prentice, Jonathan Shamash, Neal Shore, Ralph, Hauke, Luke Nordquist, Brian Lewis, Paul Monk, Michael Morris, Ryan Reddy, Xiao Wei, Michael Schweizer, Daniel George, Hyun Kim, Christopher Logothetis, David Wise, Meredith Ann McKean, Mark Fleming, David Buck, Allen Cohn, Kathryn Hitchcock, Ariel Nelson, Glenn Bubley, Bobby Liaw, Thomas Hutson, Stephan Kendall